Abstract
Four different classes of HDACs have been identified in humans so far. Classes I, II and IV are zinc-dependent amidohydrolases, while III is a family of phylogenetically conserved NAD-dependent protein deacetylases/ADP-ribosyltransferase with a welldefined role in modifying chromatin conformation and altering the accessibility of the damaged sites of DNA for repair enzymes. Sirtuins are histone deacetylases (HDACs) of class III that cleave off acetyl groups from acetyl-lysine residues in histones and non-histone proteins. As sirtuins are involved in many physiological and pathological processes, their activity has been associated with different human diseases, including cancer. Especially two sirtuin members, SIRT1 and SIRT2, have been found to antagonize p53-dependent transcriptional activation and apoptosis in response to DNA damage by catalyzing p53 deacetylation. The findings that SIRT1 levels are increased in a number of tumors highlight the oncogenic role of sirtuins, in particular, in the down-modulation of p53 oncosuppressor activity. Along this lane, cancers carrying wild-type (wt) p53 protein are known to deregulate its activity by other mechanisms. Therefore, inhibition of SIRT1 and SIRT2, aimed at restoring wt-p53 transcriptional activity in tumors that retain the ability to express normal p53, might represent a valid therapeutic cancer approach specially when combined with standard therapies. This review will be focused on sirtuin inhibitors, with a specific attention on inhibitors of SIRT1 and SIRT2. Among them, nicotinamide and its analogs, sirtinol, A3 and M15, splitomicin, HR73 and derivatives, cambinol and derivatives, EX 527, kinase inhibitors, suramin, 4-dihydropyridine derivatives, tenovins, TRIPOS 360702, AC 93253, 3-arylideneindolinones, CSC8 and CSC13 will also be described.
Keywords: Antitumoral activity, sirtuin, inhibitors, SIRT1, SIRT2
Current Medicinal Chemistry
Title:Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Volume: 19 Issue: 34
Author(s): G. Botta, L. P. De Santis and R. Saladino
Affiliation:
Keywords: Antitumoral activity, sirtuin, inhibitors, SIRT1, SIRT2
Abstract: Four different classes of HDACs have been identified in humans so far. Classes I, II and IV are zinc-dependent amidohydrolases, while III is a family of phylogenetically conserved NAD-dependent protein deacetylases/ADP-ribosyltransferase with a welldefined role in modifying chromatin conformation and altering the accessibility of the damaged sites of DNA for repair enzymes. Sirtuins are histone deacetylases (HDACs) of class III that cleave off acetyl groups from acetyl-lysine residues in histones and non-histone proteins. As sirtuins are involved in many physiological and pathological processes, their activity has been associated with different human diseases, including cancer. Especially two sirtuin members, SIRT1 and SIRT2, have been found to antagonize p53-dependent transcriptional activation and apoptosis in response to DNA damage by catalyzing p53 deacetylation. The findings that SIRT1 levels are increased in a number of tumors highlight the oncogenic role of sirtuins, in particular, in the down-modulation of p53 oncosuppressor activity. Along this lane, cancers carrying wild-type (wt) p53 protein are known to deregulate its activity by other mechanisms. Therefore, inhibition of SIRT1 and SIRT2, aimed at restoring wt-p53 transcriptional activity in tumors that retain the ability to express normal p53, might represent a valid therapeutic cancer approach specially when combined with standard therapies. This review will be focused on sirtuin inhibitors, with a specific attention on inhibitors of SIRT1 and SIRT2. Among them, nicotinamide and its analogs, sirtinol, A3 and M15, splitomicin, HR73 and derivatives, cambinol and derivatives, EX 527, kinase inhibitors, suramin, 4-dihydropyridine derivatives, tenovins, TRIPOS 360702, AC 93253, 3-arylideneindolinones, CSC8 and CSC13 will also be described.
Export Options
About this article
Cite this article as:
Botta G., P. De Santis L. and Saladino R., Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins, Current Medicinal Chemistry 2012; 19 (34) . https://dx.doi.org/10.2174/092986712804143303
DOI https://dx.doi.org/10.2174/092986712804143303 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents and Advances in the Next-Generation Sequencing Technologies
Recent Patents on Biomedical Engineering (Discontinued) Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Cardiac Telocytes
Current Stem Cell Research & Therapy Tomographic Imaging Methods and Gated Technique in Nuclear Cardiology: A Review on Current Status and Future Developments
Recent Patents on Medical Imaging Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet the Editorial Board:
Current Drug Targets